Community hub
0 subscribers7 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to Trevogrumab.
Nothing was collected or created yet.
Trevogrumab
View on Wikipediafrom Wikipedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | growth differentiation factor 8 |
| Clinical data | |
| Other names | REGN1033 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6374H9884N1696O2018S46 |
| Molar mass | 144037.80 g·mol−1 |
Trevogrumab (INN;[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. Sometimes it is combined with Garetosmab.
This drug was developed by Regeneron Pharmaceuticals, Inc.[2]
References
[edit] | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |